Genentech Reports P-III (STARGLO) Trial Data on Columvi for R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Shots:

• Genentech has reported 2yr. P-III (STARGLO) trial data assessing Columvi + GemOx vs Rituxan + GemOx in previously treated ASCT-ineligible r/r DLBCL pts
• At 24.7mos. mFU, trial showed a 40% improvement in OS (mOS: not reached vs 13.5mos.), a 59% reduction in risk of progression or death, & CRs in 58.5% vs 25.3% pts; among CR pts, 89% were alive & 82% maintained remission 1yr. post-treatment. Data to be presented at ASCO 2025
• Columvi is also being evaluated in P-III (SKYGLO) trial in combination with Polivy + Rituxan, cyclophosphamide, doxorubicin & prednisone (Pola-R-CHP) vs Pola-R-CHP in previously untreated DLBCL pts

Ref:  Businesswire| Image: Genentech | Press Release

Related News:- Genentech Collaborates with Orionis to Identify and Develop Molecular Glue Therapies for Cancer Targets

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com